.Enterprise Value to EBITDA (EV/EBITDA)
Difficulty: Intermediate
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Allergan PLC, EBITDA calculation
USD $ in thousands
| 12 months ended | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
|---|---|---|---|---|---|---|
| | Net income (loss) attributable to shareholders | |||||
| | Add: Net income attributable to noncontrolling interest | |||||
| | Less: Income (loss) from discontinued operations, net of tax | |||||
| | Add: Income tax expense | |||||
| | Earnings before tax (EBT) | |||||
| | Add: Interest expense | |||||
| | Earnings before interest and tax (EBIT) | |||||
| | Add: Depreciation | |||||
| | Add: Amortization | |||||
| | Earnings before interest, tax, depreciation and amortization (EBITDA) |
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Allergan PLC's EBITDA increased from 2015 to 2016 but then declined significantly from 2016 to 2017. |
Enterprise Value to EBITDA Ratio, Current
Allergan PLC, current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (USD $ in thousands) | |
| Enterprise value (EV) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | |
| Ratio | |
| EV/EBITDA | |
| Benchmarks | |
| EV/EBITDA, Competitors | |
| Abbott Laboratories | |
| AbbVie Inc. | |
| Amgen Inc. | |
| Biogen Inc. | |
| Bristol-Myers Squibb Co. | |
| Celgene Corp. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| EV/EBITDA, Sector | |
| Pharmaceuticals & Biotechnology | |
| EV/EBITDA, Industry | |
| Health Care | |
If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Allergan PLC, historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in thousands) | ||||||
| | Enterprise value (EV)1 | |||||
| | Earnings before interest, tax, depreciation and amortization (EBITDA)2 | |||||
| Ratio | ||||||
| | EV/EBITDA3 | |||||
| Benchmarks | ||||||
| EV/EBITDA, Competitors | ||||||
| Abbott Laboratories | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Biogen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Celgene Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals & Biotechnology | ||||||
| EV/EBITDA, Industry | ||||||
| Health Care | ||||||
2017 Calculations
3 EV/EBITDA = EV ÷ EBITDA
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| EV/EBITDA | EV/EBITDA is a valuation indicator for the overall company rather than common stock. | Allergan PLC's EV/EBITDA ratio declined from 2015 to 2016 and from 2016 to 2017. |
